Beaudry Hélène, Gendron Louis, Guimond Marie-Odile, Payet Marcel D, Gallo-Payet Nicole
Service of Endocrinology, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada J1H 5N4.
Endocrinology. 2006 Sep;147(9):4263-72. doi: 10.1210/en.2006-0411. Epub 2006 Jun 1.
The aim of the present study was to investigate whether protein kinase C (PKC) isoforms may be among the putative candidates implicated in the primary effects of the Ang II type 2 (AT2) receptor. Western blot analyses revealed the presence of PKC alpha,epsilon, iota, and zeta in NG108-15 cells. After a 3-d treatment with 3 nm Gö6976, a specific inhibitor of classical PKC isoforms, cells were characterized by the presence of one elongated process similar to that observed after treatment with Ang II or with CGP42112, a selective AT2 receptor agonist. Similar findings were observed in cells expressing a dominant-negative mutant of PKC alpha (K368A). Inhibition of PKC alpha in NG108-15 cells also decreased cell number and proliferation. In conditions of acute stimulation, Ang II induced a time-dependent and transient inhibition of PKC alpha activity, as well as a decrease in PKC alpha levels associated with the membrane. Treatment of cells with Gö6976 was also found to inhibit p21(ras) (between 1-10 min) but stimulated Rap1 activity (1-5 min) in a time-course similar to that of Ang II. Incubation of NG108-15 cells with Gö6976 (3 nm) inhibited basal p42/p44(mapk) phosphorylation, but failed to interfere with its activation by the AT(2) receptor, indicating that inhibition of PKC alpha is not directly involved in the Rap1-MEK-p42/p44(mapk) cascade. Taken together, these results indicate that PKC alpha is a primary target of the AT2 receptor. Inhibition of PKC alpha leads to a decrease in both p21(ras) activity and cell proliferation, which may facilitate AT2 receptor signaling through p42/p44(mapk), thereby leading to neurite outgrowth.
本研究的目的是调查蛋白激酶C(PKC)亚型是否可能是参与血管紧张素II 2型(AT2)受体主要效应的假定候选分子。蛋白质印迹分析显示NG108 - 15细胞中存在PKCα、ε、ι和ζ。在用3 nM Gö6976(一种经典PKC亚型的特异性抑制剂)处理3天后,细胞的特征是存在一个细长的突起,类似于用血管紧张素II或选择性AT2受体激动剂CGP42112处理后观察到的情况。在表达PKCα显性负性突变体(K368A)的细胞中也观察到了类似的结果。抑制NG108 - 15细胞中的PKCα也会减少细胞数量和增殖。在急性刺激条件下,血管紧张素II诱导PKCα活性的时间依赖性和短暂抑制,以及与膜相关的PKCα水平降低。还发现用Gö6976处理细胞会抑制p21(ras)(1 - 10分钟之间),但在与血管紧张素II相似的时间进程中刺激Rap1活性(1 - 5分钟)。用Gö6976(3 nM)孵育NG108 - 15细胞会抑制基础p42/p44(mapk)磷酸化,但未能干扰其被AT(2)受体激活,这表明抑制PKCα不直接参与Rap1 - MEK - p42/p44(mapk)级联反应。综上所述,这些结果表明PKCα是AT2受体的主要靶点。抑制PKCα会导致p21(ras)活性和细胞增殖减少,这可能通过p42/p44(mapk)促进AT2受体信号传导,从而导致神经突生长。